Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma

Trial Profile

An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APX 005M (Primary) ; Ipilimumab (Primary) ; NEO-PV 01 (Primary) ; Nivolumab (Primary) ; Poly ICLC (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Neon Therapeutics
  • Most Recent Events

    • 27 Nov 2019 Status changed from recruiting to active, no longer recruiting.
    • 20 Nov 2019 According to a Neon Therapeutics media release, the company plans to cease future enrollment in its NT-003 trial in metastatic melanoma.
    • 13 May 2019 According to a Neon Therapeutics media release, the company plans to announce immune monitoring data from this study in 2H 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top